Baricitinib + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Juvenile Idiopathic Arthritis
Conditions
Juvenile Idiopathic Arthritis
Trial Timeline
Dec 17, 2018 → Jan 26, 2022
NCT ID
NCT03773978About Baricitinib + Placebo
Baricitinib + Placebo is a phase 3 stage product being developed by Eli Lilly for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03773978. Target conditions include Juvenile Idiopathic Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07222332 | Phase 3 | Recruiting |
| NCT07222137 | Phase 3 | Recruiting |
| NCT05237388 | Phase 2 | Recruiting |
| NCT05723198 | Phase 3 | Recruiting |
| NCT04421027 | Phase 3 | Completed |
| NCT03843125 | Phase 3 | Terminated |
| NCT03899259 | Phase 3 | Completed |
| NCT03742973 | Phase 2 | Terminated |
| NCT03773978 | Phase 3 | Completed |
| NCT03570749 | Phase 2/3 | Completed |
| NCT03616964 | Phase 3 | Completed |
| NCT03616912 | Phase 3 | Terminated |
| NCT03334435 | Phase 3 | Completed |
| NCT03435081 | Phase 3 | Completed |
| NCT03334422 | Phase 3 | Completed |
| NCT03334396 | Phase 3 | Completed |
| NCT02758613 | Phase 1 | Completed |
| NCT02708095 | Phase 2 | Completed |
| NCT02265705 | Phase 3 | Completed |
| NCT01885078 | Phase 3 | Completed |
Competing Products
20 competing products in Juvenile Idiopathic Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX-200 + Placebo | Polaryx Therapeutics | Phase 3 | 69 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Adalimumab | Eisai | Phase 3 | 77 |
| Abatacept | Ono Pharmaceutical | Phase 3 | 77 |
| Ixekizumab + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Tocilizumab | Eli Lilly | Phase 3 | 77 |
| adalimumab + Methotrexate | AbbVie | Pre-clinical | 23 |
| Upadacitinib | AbbVie | Phase 1 | 33 |
| Upadacitinib + Tocilizumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Risankizumab | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| naproxen + esomeprazole | AstraZeneca | Phase 1 | 33 |
| Alendronate (Fosamax) | Merck | Pre-clinical | 23 |
| canakinumab | Novartis | Phase 3 | 77 |
| Secukinumab | Novartis | Phase 1 | 33 |
| ACZ885 150 mg (Canakinumab) | Novartis | Phase 3 | 77 |